Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of bacteroides fragilis and immune checkpoint inhibitor

A technology of Bacteroides fragilis, immune checkpoint, applied in the field of biomedicine

Active Publication Date: 2022-04-12
GUANGZHOU ZHIYI PHARMA INC
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no probiotic product for the treatment of lymphoma in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of bacteroides fragilis and immune checkpoint inhibitor
  • New application of bacteroides fragilis and immune checkpoint inhibitor
  • New application of bacteroides fragilis and immune checkpoint inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Embodiment 1: the fermentation culture of Bacteroides fragilis

[0060] Streak inoculation of Bacteroides fragilis ZY-312 strain on blood plate, anaerobic culture for 48h. Observe the colony morphological characteristics, staining characteristics, size, club shape and distribution, etc.

[0061] Colony characteristics: Bacteroides fragilis ZY-312, after being cultured on a blood plate for 48 hours, is slightly convex, translucent, white, smooth, non-hemolytic, and the diameter of the colony is between 1-3mm. See figure 1 .

[0062] Morphology under the microscope: Bacteroides fragilis ZY-312 was examined by Gram staining. It is a Gram-negative bacterium with a typical rod shape, blunt rounded ends and dense staining. The uncolored part in the middle of the bacteria is like a vacuole. figure 2 .

[0063] Select a single colony and inoculate it in a plant-derived peptone liquid medium for fermentation and culture for 8 hours (at a temperature of 37°C). The obtained ba...

Embodiment 2

[0064] Embodiment 2: Preparation of Bacteroides fragilis live bacteria liquid

[0065] (1) Streak-inoculate the strain on a blood plate, and incubate anaerobically at 37°C for 48 hours.

[0066] Colony characteristics: Bacteroides fragilis ZY-312, after being cultured on a blood plate for 48 hours, is slightly convex, translucent, white, smooth, non-hemolytic, and the diameter of the colony is 1-3mm.

[0067] (2) Bacterial enrichment: select a single colony from step (1) and inoculate it in TSB (tryptone soybean broth, containing 5% fetal bovine serum) for enrichment culture, and the obtained bacterial solution is preserved for future use.

[0068] (3) Viable Bacteroides fragilis solution: the bacteria solution prepared in step (1) was measured with a McFarland turbidimetric tube and diluted to 10 with normal saline. 7 CFU / ml and 10 9 CFU / ml, save for future use.

Embodiment 3

[0069] Embodiment 3: Preparation of the inactivated bacteria powder of Bacteroides fragilis

[0070] (1) Get the Bacteroides fragilis fermented liquid that embodiment 1 makes and carry out centrifugation to fermented liquid, collect wet thallus, add physiological saline according to thalline: physiological saline=1:(10-30) (m:v) ratio The bacteria sludge was resuspended and washed, and the washed bacteria were collected by centrifugation again.

[0071] (2) Add the excipient that 5wt% maltodextrin+0.9wt% sodium chloride is mixed to step (1) gained thalline, press thallus: excipient=1:(5-15)(m:m ) ratio, stir and disperse, heat inactivate (20-40)±5 minutes at (70-100)±5°C to obtain inactivated bacteria solution.

[0072] (3) Centrifuge the inactivated bacteria liquid obtained in step (2) to collect the inactivated bacteria sludge.

[0073] (4) Add excipients to the inactivated bacteria slime collected in step (3) to make the total weight consistent with the weight of the bact...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel application of Bacteroides fragilis and an immune checkpoint inhibitor. The invention relates to application of a combination of bacteroides fragilis and an immune checkpoint inhibitor in preparation of a medicine for preventing and treating lymphoma. The preservation number of the bacteroides fragilis is CGMCC No.10685. Compared with the prior art, the invention has the following beneficial effects: a large number of experiments prove that the Bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685 is combined with an immune checkpoint inhibitor for use, especially a PD-1 inhibitor for use, so that the Bacteroides fragilis ZY-312 has a synergistic effect on lymphoma.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a new application of Bacteroides fragilis and immune checkpoint inhibitors. Background technique [0002] Lymphoma (lymphoma) is a malignant tumor originating from the lymphatic hematopoietic system, which can be divided into two types: non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). The incidence of NHL is about 10 times that of HL. The mortality rate of NHL is 20 times that of HL. The pathological feature of Hodgkin lymphoma is that the tumor tissue contains lymphocytes, eosinophils, plasma cells and specific Reed-Steinberg cells, and HL is divided into nodular lymphoid-rich Cellular and classical (cHL), cHL is the most common type of Hodgkin's lymphoma, accounting for about 90%, including lymphocyte-predominant, nodular sclerosis, mixed cellularity and lymphocyte depletion. NHL is the sum of a group of independent diseases with strong heterogeneity. Pathologically, it ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K35/741A61K39/395A61P35/00
CPCY02A50/30A61K39/395A61P35/00A61K45/06A61K35/741
Inventor 王晔易晓敏黄烁雅王薇
Owner GUANGZHOU ZHIYI PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com